Menu
Logo

PROGRESSION-FREE SURVIVAL**1,2

71
**Data are taken from the SPARTAN study where patients had a PSA doubling time of ≤10 months, despite ADT. Median time to metastasis was 40.5
months for patients receiving ERLEADA® + ADT vs 16.6 months for patients receiving placebo + ADT.
PROGRESSION-FREE SURVIVAL**1,2
REFERENCES
1- Smith MR, et al. N Engl J Med. 2018;378:1408–18.
2-Smith MR, et al. N Engl J Med. 2018;378:1408–18. Supplementary appendix.
erleada_logo

CP-142079